Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification ProjectBlood199789390939189166827
   PubMed Web of Science ®Google Scholar
• VeldersGAKluin-NelemansJCDe BoerCJMantle-cell lymphoma: a population-based clinical studyJ Clin Oncol199614126912748648383
   PubMed Web of Science ®Google Scholar
• ArgatoffLHConnorsJMKlasaRJHorsmanDEGascoyneRDMantle cell lymphoma: a clinicopathologic study of 80 casesBlood199789206720789058729
   PubMed Web of Science ®Google Scholar
• SamahaHDumontetCKettererNMantle cell lymphoma: a retrospective study of 121 casesLeukemia199812128112879697885
   PubMed Web of Science ®Google Scholar
• BoschFLopez-GuillermoACampoEMantle cell lymphoma: presenting features, response to therapy, and prognostic factorsCancer1998825675759452276
   PubMed Web of Science ®Google Scholar
• HerrmannAHosterEZwingersTImprovement of overall survival in advanced stage mantle cell lymphomaJ Clin Oncol20092751151819075279
   PubMed Web of Science ®Google Scholar
• HosterEDreylingMKlapperWA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood200811155856517962512
   PubMed Web of Science ®Google Scholar
• MartinPChadburnAChristosPOutcome of deferred initial therapy in mantle-cell lymphomaJ Clin Oncol2009271209121319188674
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol2005231984199215668467
   PubMed Web of Science ®Google Scholar
• RomagueraJEFayadLRodriguezMAHigh rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJ Clin Oncol2005237013702316145068
   PubMed Web of Science ®Google Scholar
• FayadLThomasDRomagueraJUpdate of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomasClin Lymphoma Myeloma20078Suppl 2S57S6218284717
   PubMedGoogle Scholar
• EpnerEMUngerJMillerTA multi-center trial of hyper-CVAD + rituxan in patients with newly diagnosed aggressive mantle cell lymphoma. ASH Annual Meeting AbstractsBlood2007110A387
   Google Scholar
• KahlBSLongoWLEickhoffJCMaintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology NetworkAnn Oncol2006171418142316766582
   PubMed Web of Science ®Google Scholar
• MartinPChadburnAChristosPIntensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapiesAnn Oncol2008191327133018349031
   PubMed Web of Science ®Google Scholar
• FreedmanASNeubergDGribbenJGHigh-dose chemoradio-therapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remissionJ Clin Oncol19981613189440717
   PubMed Web of Science ®Google Scholar
• VoseJMBiermanPJWeisenburgerDDAutologous hematopoietic stem cell transplantation for mantle cell lymphomaBiol Blood Marrow Transplant2000664064511128815
   PubMed Web of Science ®Google Scholar
• GeislerCHKolstadALaurellALong-term progression-free survival of mantle cell lymphoma after intensive front-line immuno-chemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood20081122687269318625886
   PubMed Web of Science ®Google Scholar
• TamCSBassettRLedesmaCMature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphomaBlood20091134144415219168784
   PubMed Web of Science ®Google Scholar
• TillBGGooleyTACrawfordNEffect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaLeuk Lymphoma2008491062107318452065
   PubMed Web of Science ®Google Scholar
• DamonLEJohnsonJLNiedzwieckiDImmunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909J Clin Oncol2009276101610819917845
   PubMed Web of Science ®Google Scholar
• FisherRIBernsteinSHKahlBSMulticenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol2006244867487417001068
   PubMed Web of Science ®Google Scholar
• BelchAKouroukisCTCrumpMA phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150Ann Oncol20071811612116971665
   PubMed Web of Science ®Google Scholar
• GoyAYounesAMcLaughlinPPhase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphomaJ Clin Oncol20052366767515613697
   PubMed Web of Science ®Google Scholar
• O’ConnorOAWrightJMoskowitzCPhase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphomaJ Clin Oncol20052367668415613699
   PubMed Web of Science ®Google Scholar
• KoenigsmannMKnaufWHeroldMFludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the East German Society of Hematology And Oncology (OSHO)Leuk Lymphoma2004451821182715223642
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol2005233383338915908650
   PubMed Web of Science ®Google Scholar
• HeroldMSchulzeANiederwieserDBendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)J Cancer Res Clin Oncol200613210511216088404
   PubMed Web of Science ®Google Scholar
• WeideRHessGKopplerHHigh anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma2007481299130617613757
   PubMed Web of Science ®Google Scholar
• KaufmannHRadererMWohrerSAntitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphomaBlood20041042269227115166030
   PubMed Web of Science ®Google Scholar
• HabermannTMLossosISJusticeGLenalidomide oral mono-therapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaBr J Haematol200914534434919245430
   PubMed Web of Science ®Google Scholar
• AnsellSMInwardsDJRowlandKMJrLow-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupCancer200811350851418543327
   PubMed Web of Science ®Google Scholar
• WitzigTEGeyerSMGhobrialIPhase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaJ Clin Oncol2005235347535615983389
   PubMed Web of Science ®Google Scholar
• GeorgakisGVYounesAFrom Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapyExpert Rev Anticancer Ther2006613114016375650
   PubMed Web of Science ®Google Scholar
• EngCPSehgalSNVezinaCActivity of rapamycin (AY-22,989) against transplanted tumorsJ Antibiot (Tokyo)198437123112376501094
   PubMed Web of Science ®Google Scholar
• BjornstiMAHoughtonPJThe TOR pathway: a target for cancer therapyNat Rev Cancer2004433534815122205
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMDefining the role of mTOR in cancerCancer Cell20071292217613433
   PubMed Web of Science ®Google Scholar
• RobertFPelletierJTranslation initiation: a critical signalling node in cancerExpert Opin Ther Targets2009131279129319705976
   PubMed Web of Science ®Google Scholar
• BertoniFZuccaECotterFEMolecular basis of mantle cell lymphomaBr J Haematol200412413014014687022
   PubMed Web of Science ®Google Scholar
• RousseauDKasparRRosenwaldIGehrkeLSonenbergNTranslation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4EProc Natl Acad Sci U S A199693106510708577715
   PubMed Web of Science ®Google Scholar
• AverousJFonsecaBDProudCGRegulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1Oncogene2008271106111317724476
   PubMed Web of Science ®Google Scholar
• ManningBDBalancing Akt with S6K: implications for both metabolic diseases and tumorigenesisJ Cell Biol200416739940315533996
   PubMed Web of Science ®Google Scholar
• ManningBDLogsdonMNLipovskyAIAbbottDKwiatkowskiDJCantleyLCFeedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2Genes Dev2005191773177816027169
   PubMed Web of Science ®Google Scholar
• StambolicVSuzukiAde la PompaJLNegative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTENCell19989529399778245
   PubMed Web of Science ®Google Scholar
• SansalISellersWRThe biology and clinical relevance of the PTEN tumor suppressor pathwayJ Clin Oncol2004222954296315254063
   PubMed Web of Science ®Google Scholar
• SakaiAThieblemontCWellmannAJaffeESRaffeldMPTEN gene alterations in lymphoid neoplasmsBlood199892341034159787181
   PubMed Web of Science ®Google Scholar
• ThompsonJEThompsonCBPutting the rap on AktJ Clin Oncol2004224217422615483033
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMAn expanding role for mTOR in cancerTrends Mol Med20051135336116002336
   PubMed Web of Science ®Google Scholar
• RosenwaldIBLazaris-KaratzasASonenbergNSchmidtEVElevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4EMol Cell Biol199313735873638246956
   PubMed Web of Science ®Google Scholar
• RosenwaldIBKasparRRousseauDEukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levelsJ Biol Chem199527021176211807673150
   PubMed Web of Science ®Google Scholar
• WangSRosenwaldIBHutzlerMJExpression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin’s lymphomasAm J Pathol199915524725510393856
   PubMed Web of Science ®Google Scholar
• PolunovskyVARosenwaldIBTanATTranslational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated MycMol Cell Biol199616657365818887686
   PubMed Web of Science ®Google Scholar
• MollerMBNielsenOPedersenNTOncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin’s lymphoma entitiesMod Pathol1999121010101610574597
   PubMed Web of Science ®Google Scholar
• IritaniBMEisenmanRNc-Myc enhances protein synthesis and cell size during B lymphocyte developmentProc Natl Acad Sci U S A199996131801318510557294
   PubMed Web of Science ®Google Scholar
• HauptYHarrisAWAdamsJMRetroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-mycOncogene199279819861570158
   PubMed Web of Science ®Google Scholar
• TanABittermanPSonenbergNPetersonMPolunovskyVInhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1Oncogene2000191437144710723135
   PubMed Web of Science ®Google Scholar
• RuggeroDMontanaroLMaLThe translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesisNat Med20041048448615098029
   PubMed Web of Science ®Google Scholar
• BaconALHarrisALHypoxia-inducible factors and hypoxic cell death in tumour physiologyAnn Med20043653053915513303
   PubMed Web of Science ®Google Scholar
• ZhongHMabjeeshNWillardMSimonsJNuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditionsCancer Lett200218123323812175540
   PubMed Web of Science ®Google Scholar
• MazureNMChenEYLaderouteKRGiacciaAJInduction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional elementBlood199790332233319345014
   PubMed Web of Science ®Google Scholar
• DunlopEATeeARMammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanismsCell Signal20092182783519166929
   PubMed Web of Science ®Google Scholar
• OttMMBartkovaJBartekJCyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activityBlood199790315431599376597
   PubMed Web of Science ®Google Scholar
• RudeliusMPittalugaSNishizukaSConstitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphomaBlood20061081668167616645163
   PubMed Web of Science ®Google Scholar
• PeponiEDrakosEReyesGLeventakiVRassidakisGZMedeirosLJActivation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphomaAm J Pathol20061692171218017148679
   PubMed Web of Science ®Google Scholar
• Dal ColJZancaiPTerrinLDistinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphomaBlood20081115142515118339899
   PubMed Web of Science ®Google Scholar
• HashemolhosseiniSNagamineYMorleySJDesrivieresSMercepLFerrariSRapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stabilityJ Biol Chem199827314424144299603954
   PubMed Web of Science ®Google Scholar
• HippSRingshausenIOelsnerMBognerCPeschelCDeckerTInhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cellsHaematologica2005901433143416219581
   PubMed Web of Science ®Google Scholar
• DourosJSuffnessMNew antitumor substances of natural originCancer Treat Rev1981863877248995
   PubMed Web of Science ®Google Scholar
• KahanBDCamardoJSRapamycin: clinical results and future opportunitiesTransplantation2001721181119311602840
   PubMed Web of Science ®Google Scholar
• DudkinLDillingMBCheshirePJBiochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibitionClin Cancer Res200171758176411410517
   PubMed Web of Science ®Google Scholar
• GrunwaldVDeGraffenriedLRusselDFriedrichsWERayRBHidalgoMInhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cellsCancer Res2002626141614512414639
   PubMed Web of Science ®Google Scholar
• GeoergerBKerrKTangCBAntitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapyCancer Res2001611527153211245461
   PubMed Web of Science ®Google Scholar
• YuKToral-BarzaLDiscafaniCmTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancerEndocr Relat Cancer2001824925811566616
   PubMed Web of Science ®Google Scholar
• ShiYGeraJHuLEnhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779Cancer Res2002625027503412208757
   PubMed Web of Science ®Google Scholar
• RaymondEAlexandreJFaivreSSafety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerJ Clin Oncol2004222336234715136596
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med20073562271228117538086
   PubMed Web of Science ®Google Scholar
• AtkinsMBHidalgoMStadlerWMRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaJ Clin Oncol20042290991814990647
   PubMed Web of Science ®Google Scholar
• Torisel [package insert]Philadelphia, PAWyeth Pharmaceuticals, Inc.2008
   Google Scholar
• HessGHerbrechtRRomagueraJPhase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphomaJ Clin Oncol2009273822382919581539
   PubMed Web of Science ®Google Scholar
• CaiPTsaoRRuppenMEIn vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolitesDrug Metab Dispos2007351554156317540708
   PubMed Web of Science ®Google Scholar
• BoniJPLeisterCBurnsJHugBDifferential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimusBr J Cancer2008981797180218458675
   PubMed Web of Science ®Google Scholar
• LunardiGArmirottiANicodemoMComparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case seriesClin Ther2009311812181919808140
   PubMed Web of Science ®Google Scholar
• MorrisettJDAbdel-FattahGKahanBDSirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipientsTransplant Proc200335143S150S12742487
   PubMed Web of Science ®Google Scholar
• SarbassovDDAliSMSenguptaSProlonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKBMol Cell20062215916816603397
   PubMed Web of Science ®Google Scholar
• AparicioGCalvoMBMedinaVComprehensive lung injury pathology induced by mTOR inhibitorsClin Transl Oncol20091149951019661024
   PubMed Web of Science ®Google Scholar
• WendelHGDe StanchinaEFridmanJSSurvival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature200442833233715029198
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet200837244945618653228
   PubMed Web of Science ®Google Scholar
• HarituniansTMoriAO’KellyJLuongQTGilesFJKoefflerHPAntiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphomaLeukemia20072133333917136116
   PubMed Web of Science ®Google Scholar
• RizzieriDAFeldmanEDipersioJFA phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignanciesClin Cancer Res2008142756276218451242
   PubMed Web of Science ®Google Scholar
• DanceyJmTOR signaling and drug development in cancerNat Rev Clin Oncol2010720921920234352
   PubMed Web of Science ®Google Scholar